167 related articles for article (PubMed ID: 28391352)
1. The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
Kondo M; Hotta Y; Ando R; Yasui T; Kimura K
Cancer Chemother Pharmacol; 2017 May; 79(5):995-1001. PubMed ID: 28391352
[TBL] [Abstract][Full Text] [Related]
2. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX
Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
Jan AS; Dolan DE; Lombardi K; Gupta S
Clin Genitourin Cancer; 2016 Jun; 14(3):e257-63. PubMed ID: 26462439
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
5. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin for Kidney Transplant Patients With Locally Advanced Transitional Cell Carcinoma: A Single-center Experience.
Wang ZP; Wang WY; Zhu YC; Xiao J; Lin J; Guo YW; Tian Y
Transplant Proc; 2016; 48(6):2076-9. PubMed ID: 27569947
[TBL] [Abstract][Full Text] [Related]
8. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
14. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
[TBL] [Abstract][Full Text] [Related]
15. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Park JH; Lee SW; Kim HS; Kang SG; Ko YH; Kim ST; Kang SH; Park YJ; Choi IK; Oh SC; Sung DJ; Seo JH; Cheon J; Kim YH; Kim JS; Park KH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1033-9. PubMed ID: 23370665
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of pre- and postoperative gemcitabine-plus-cisplatin systemic chemotherapy for the treatment of locally advanced urothelial carcinoma in kidney transplant patients.
Zhang P; Zhang XD; Wang Y; Wang W
Transplant Proc; 2013 Nov; 45(9):3293-7. PubMed ID: 24182803
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
[TBL] [Abstract][Full Text] [Related]
19. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
20. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
